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AbsTrACT
background/Aims To investigate whether intravitreal 
injection of triamcinolone acetonide (IVTA) combined 
with vitrectomy prevents postoperative inflammation 
in patients with vitreous haemorrhage (VH) due to 
proliferative diabetic retinopathy (PDR).
Methods This prospective, multicentre, randomised 
study conducted at seven sites in Japan enrolled 
patients diagnosed as having VH following PDR. Patients 
underwent vitrectomy with (IVTA+VIT group) or without 
(VIT group) IVTA at the end of the surgery. Anterior flare 
intensity (AFI), central retinal thickness (CRT), best-
corrected visual acuity (BCVA) and intraocular pressure 
(IOP) were measured before and at 3 days, 1 week, 1, 3 
and 6 months after surgery and compared.
results Number of patients who completed 6 
months of follow-up was 40 and 41 in VIT group and 
IVTA+VIT group, respectively. AFI was significantly 
higher in the VIT group than in the IVTA+VIT group 
at 3 days (P=0.033), 1 week (P=0.019) and 1 month 
(P=0.037). There were no significant differences in 
CRT, BCVA and IOP between the groups through the 
observational periods. In the cases with macular oedema 
>350 µm of CRT at 3 days, CRT was significantly lower 
in the IVTA+VIT group than in the VIT group at 1 month 
(P=0.041).
Conclusions IVTA combined with vitrectomy and 
cataract surgery contributed to inhibit the postoperative 
inflammation in patients with VH due to PDR. The effect 
of IVTA in the reduction of diabetic macular oedema may 
be limited to the early stage after surgery.
Trial registration number UMIN000020376, Post-
results.
InTroduCTIon
Proliferative diabetic retinopathy (PDR) is one 
of the leading causes of blindness in the working 
population.1 PDR is characterised by retinal isch-
aemia and neovascularisation, which leads to 
vitreous haemorrhage (VH) and tractional retinal 
detachment. VH causes sudden visual loss and also 
interferes with panretinal photocoagulation (PRP).
Pars plana vitrectomy (PPV) can be very effec-
tive in the treatment of PDR by removing vitreous 
opacity, relieving retinal traction and performing 
PRP. With advances in technology, microinci-
sion vitrectomy surgery (MIVS) with 23-gauge, 
25-gauge and 27-gauge PPV systems has become 
the standard in clinical practice.2 3 Compared with 
non-microincision 20-gauge vitrectomy, MIVS 
is less invasive, has less postoperative inflamma-
tion, leads to faster recovery and reduces patient 
discomfort.4 5 Nevertheless, several ocular compli-
cations, such as enhancement of cell flare inten-
sity, fibrovascular proliferation and iris synechia, 
are still encountered.6 Therefore, it is important 
to prevent postoperative inflammation after 
vitrectomy.
Corticosteroids have traditionally been used 
to treat inflammation because of their ability to 
reduce leucocyte migration and cytokine produc-
tion and to antagonise the action of vascular endo-
thelial growth factor (VEGF).7 8 The effect of three 
potent synthetic corticosteroids, that is, triamcin-
olone acetonide (TA), dexamethasone and fluoci-
nolone acetonide, was investigated as a treatment 
for diabetic macular oedema (DME). In Japan, only 
intravitreal injection of TA (IVTA) has been clin-
ically approved, and several studies have demon-
strated the efficacy of IVTA for improving macular 
swelling. Moreover, TA improves the visibility 
of the hyaloid and safety of surgical procedures, 
and the posterior vitreous detachment induced 
by IVTA is currently a standard technique used in 
vitrectomy.9 Although the TA injected to visualise 
the vitreous is removed during surgery, IVTA may 
contribute to reduction of postoperative inflamma-
tion and macular swelling.
In this prospective, multicentre, randomised 
study, we investigated whether additional IVTA is 
effective for reducing postoperative inflammation 
and macular swelling in the eyes of patients with 
VH and diabetes mellitus (DM).
PATIenTs And MeThods
This study was conducted at seven clinical centres 
throughout Japan. The study protocol was approved 
by the institutional review board of each clinical 
centre, and adhered to the tenets of the Declaration 
of Helsinki. The protocol and the safety and efficacy 
implications of the interventions were explained 
to all participants before enrolment. All patients 
provided informed consent. This study was regis-
tered with the University Hospital Medical Infor-
mation Network Clinical Trials Registry (UMIN) of 
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Japan (ID UMIN 000020376; date of access and registration, 28 
December 2015).
Patient eligibility and exclusion criteria
Patients with type 2 diabetes who required vitrectomy for VH 
were eligible for this study. Preoperatively, at 3 days, 1 week, 1, 
3 and 6 months after surgery, all patients underwent a complete 
ophthalmic examination, including best-corrected visual acuity 
(BCVA), Goldman application tonometry, fundus examination, 
laser flare meter and optical coherence tomography (OCT) 
(SPECTRALIS: Heidelberg Engineering, Vista, California, USA). 
BCVA was converted to the logarithm of the minimum angle 
of resolution scale. The major exclusion criteria included: (1) 
history of injection of anti-VEGF drugs and steroids and retinal 
photocoagulation within 3 months before surgery, (2) active 
intraocular inflammation or infection in either eye, (3) uncon-
trolled glaucoma in either eye, (4) retinal detachment, (5) history 
of stroke and (6) systolic blood pressure (BP) >160 mm Hg or 
diastolic BP >100 mm Hg or untreated hypertension.
Patients were randomised at a 1:1 allocation ratio to either 
vitrectomy treatment (the VIT group) or combination treatment 
with vitrectomy followed by IVTA (the VIT+IVTA group) by 
the covariate adaptive randomisation. The research investigator 
was not involved in the process of randomisation. Although the 
patients and study physicians were not blinded to the therapeutic 
modality, the OCT technician and all statisticians were blinded 
to the randomisation of patients.
After local anaesthesia by a sub-Tenon capsule injection of lido-
caine hydrochloride, a standard four-port PPV was performed 
by using 25-gauge microincision procedures with chandelier 
illumination (Constellation Vision System; Alcon, Irvine, Cali-
fornia, USA). All patients basically underwent the same proce-
dure except for the treatment of IVTA at the end of the surgery. 
During the vitrectomy, all patients received photocoagulation 
using a laser system (Purepoint, 532 nm), which was equipped 
with the Constellation Vision System (Alcon). We applied PRP 
burns around the retinal vascular arcade as far peripheral as just 
anterior to ora serrata. The laser power setting was 120–160 mW, 
the duration was 0.2 s, and the interval was 0.2 s. The laser power 
was set strong enough to cause a white spot to appear on the 
retina. MaQaid (40 mg/phial) was purchased from Wakamoto 
Pharmaceutical (Tokyo, Japan). MaQaid was dissolved in 1 mL 
Balanced Salt Solution Plus (Alcon Laboratories, Fort Worth, 
Texas, USA), and 0.2 mL of the solution was separated and kept 
in a 1 mL syringe. In the IVTA+VIT group, 0.1 mL (4 mg) was 
injected into the vitreous cavity through a 30-gauge needle at 
the end of the surgery. The remaining solution (0.8 mL) was 
diluted fourfold to achieve a final concentration of 10 mg/mL 
to visualise the vitreous body during the surgical procedure, and 
the vitreous membrane, including the posterior hyaloid portion, 
were completely removed.
Phakic patients also underwent phacoemulsification and 
implantation of the intraocular lens (IOL) via a foldable IOL 
with a round 7.0 mm (Eternity NX-70; Santen, Osaka, Japan) 
prior to the vitrectomy but only on patients who were >50 years 
old and had a cataract that prevented a clear view of the retina 
during surgery. Postoperatively, all patients received similar 
routine medications, bromfenac sodium two times per day, beta-
methasone and levofloxacin three times per day for 3 months. If 
the epiretinal membrane (ERM) was present, that was removed 
during surgery. Also, if DME was noticed during vitrectomy, the 
internal limiting membrane (ILM) peeling were carried out with 
the aid of the staining using 0.025% Brilliant Blue G (ILM Blue, 
DORC, Zuidland, The Netherlands).
A laser flare cell photometer (FM-600 or FM-700; Kowa, 
Nagoya, Japan) was used to quantify the degree of aqueous flare 
and cells according to the manufacturer’s protocol. Laser cell 
measurements were performed preoperatively and at 3 days, 
1 week, 1, 3 and 6 months postoperatively. Measurements were 
taken 30 min after the application of 0.5% tropicamide and 
0.5% phenylephrine hydrochloride (Mydrin P, Santen), repeated 
10 times, and then averaged to obtain final results for flare inten-
sity. Central retinal thickness (CRT) was measured by using OCT 
map mode 3 days, 1 week, 1, 3 and 6 months after vitrectomy.
A sample size of 38 subjects in each group would have 
provided 80% power to show, at a two-sided α-level of 0.05 and 
an effect size of 0.8, the superiority of the combination therapy 
with IVTA compared with VIT monotherapy. The significance of 
Figure 1 Diagram showing the study design. Eligible eyes were randomised 1:1 to receive a vitrectomy with or without intravitreal injection of 
triamcinolone acetonide (IVTA).
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differences in age, duration of DM and level of haemoglobin A1c 
between the two study groups was analysed using an unpaired 
t-test. The significance of the differences in flare intensity, intra-
ocular pressure (IOP), CRT and BCVA was analysed by using 
the Mann-Whitney U test. Bartlett’s test was used to examine 
the equal variances across samples. After inspecting the normal 
distribution of the data, CRT, flare values, IOP or BCVA among 
the different time points were compared by using the Wilcoxon 
signed-rank test. Differences with P<0.05 were considered as 
indicating statistical significance. The data were presented as the 
mean±SE.
resulTs
Eighty-four eyes of 84 patients were examined in this study 
between 3 April 2016 and 31 January 2017. Forty-two patients 
were randomised to the VIT+IVTA group and 42 to the VIT 
group. During the vitrectomy, the fibrovascular tissue was 
noticed in 13 (31%) and 15 (36%) cases of VIT group and 
VIT+IVTA group, respectively. Tractional retinal detach-
ment was complicated in two cases of the VIT group, and gas 
or silicon oil tamponade was performed. These cases were 
excluded from this study (figure 1). Additionally, one patient 
in the VIT+IVTA group exited the study because his last visit 
was at 1 month after surgery, so the required follow-up at 6 
months could not be performed. Thus, the resultant numbers of 
patients who completed 6 months of follow-up were 40 and 41 
in the VIT group and IVTA+VIT group, respectively (figure 1). 
Table 1 shows the baseline characteristics at registration for the 
two groups. There were no significant differences in the general 
medical history or ophthalmological factors between the two 
groups. Table 2 shows the data of surgical parameters, including 
the combination of cataract surgery, removal of fibrovascular 
tissue and ERM, ILM peeling, number of laser shots and the 
surgical time. No significant difference in these parameters was 
found between the groups.
We compared the temporal profiles of CRT, BCVA, IOP and 
anterior flare intensity (AFI) between the IVTA+VIT group and 
VIT group (figures 2 and 3). AFI dramatically increased at day 
3 in both groups, then gradually decreased. The AFI was signifi-
cantly lower in the IVTA+VIT group than in the VIT group at 
day 3 (P=0.033), 1 week (P=0.019) and 1 month (P=0.037) 
(figure 2A). Since cataract surgery might influence on the ante-
rior inflammation, we separately analysed the changes of AFI in 
the eyes underwent vitrectomy with or without cataract surgery. 
Similar to the results of all cases, AFI in the IVTA+VIT group 
was significantly lower than that of VIT group at day 3 
(P=0.026), 1 week (P=0.012) and 1 month (P=0.021) in the 
patients underwent vitrectomy combined with cataract surgery 
(figure 2B). In the eyes underwent vitrectomy, significant differ-
ence was also found at day 3 (P=0.031), 1 week (P=0.018) and 
1 month (P=0.015) postoperatively (figure 2C). In the values 
of CRT (figure 3A), BCVA (figure 3B) and IOP (figure 3C), no 
significant differences were found between the groups at any 
time points. In both groups, BCVA dramatically improved at 
day 3 and thereafter postoperatively, and the final BCVA values 
were 0.195±0.048 and 0.251±0.059 in the VIT group and 
IVTA+VIT group, respectively.
The number of laser shots was significantly correlated 
with AFI at 1 week (P=0.024, R2=0.162) in the VIT group 
(figure 4A). On the other hand, the relationship between the 
number of laser spots and the flare intensity was insignificant 
in the IVTA+VIT group (figure 4B). There was no significant 
correlation between the surgical time and AFI at any time point 
in each group.
We investigated whether additional IVTA could reduce the 
CRT in the patients with significant macular oedema. In this study, 
the measurement of CRT was initiated from day 3 after surgery 
because VH disturbed the OCT measurement before surgery. The 
average CRT values at 3 days after surgery were 328±19 µm and 
330±14 µm in the VIT group and VIT+IVTA group, respectively. 
The percentages of the patients with macular oedema >350 µm 
measured at day 3 were 42.5% (17/40) and 43.9% (18/41) in the 
VIT group and VIT+IVTA group, respectively. All patients who 
underwent the removal of ERM (nine cases in VIT group, seven 
cases in IVTA+VIT group) were included these macular oedema 
group. Also, in these macular oedema subgroup, most of patients, 
94.4% (17/18) in the IVTA +VIT group and 94.1% (16/17) in 
the VIT group, underwent ILM peeling during vitrectomy. We 
focused on these patients with DME and performed a subanal-
ysis of the effect of the combination of IVTA (figure 5A). In both 
groups, CRT gradually decreased, and the difference from baseline 
became significant at 6 months after surgery. The CRT was signifi-
cantly lower in the IVTA+VIT group than in the VIT group at 
1 month (P=0.038). In both groups, acute improvement of BCVA 
were observed after surgery. Even if DME was present, BCVA 
was improved from 1.17±0.21 to 0.47±0.08 in the VIT group, 
and from 1.12±0.24 to 0.36±0.07 in the IVTA+VIT group 
during 1 month after surgery. The final BCVA values at 6 months 
were 0.274±0.088 and 0.372±0.076 in the VIT group and 
IVTA+VIT group, respectively. No significant difference in visual 
acuity was found between the groups (figure 5B).
Recurrent VH occurred after surgery in 3 (7.1%) and 2 (4.8%) 
cases of VIT group and VIT+IVTA group, respectively. The 





Age (years) 67.3±8.2 66.9±8.5 0.44*
Gender (male/female) 22/20 23/19 0.61† 
Duration of DM (years) 11.3±1.3 12.1±1.5 0.26*
Haemoglobin A1c (%) 7.4±0.4 7.3±0.3 0.54*
Insulin therapy 23 (54.8%) 21 (50.0%) 0.66† 
Serum creatinine 2.34±0.47 2.28±0.52 0.42*
Left eye:right eye 20:22 23:19 0.51† 
*Mann-Whitney U test.
†χ2 test.
DM, diabetes mellitus; IVTA, intravitreal injection of triamcinolone acetonide; VIT, 
vitrectomy treatment. 





Combination of cataract surgery 31 (73.8%) 33 (78.6%) 0.61*
Lens-sparing vitrectomy 2 (4.8%) 0 (0%) 0.15*
Removal of fibrovascular tissue 13 (31.0%) 15 (35.7%) 0.64*
ERM peeling 9 (21.4%) 7 (16.7%) 0.58*
ILM peeling 19 (45.2%) 21 (50.0%) 0.83
Number of laser spots 1122±144 1208±98 0.44† 
Surgical time (min)
  VIT 54±3 51±4 0.46† 
  VIT+cataract surgery 63±5 65±6 0.41† 
*χ2 test.
†Mann-Whitney U test.
ERM, epiretinal membrane; ILM, internal limiting membrane; IVTA, intravitreal 
injection of triamcinolone acetonide; VIT, vitrectomy treatment. 
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Figure 2 Changes in the intensity of flare in the eyes of the patients who underwent vitrectomy (VIT group) or vitrectomy combined with 
intravitreal triamcinolone acetonide (IVTA) (VIT+IVTA group). (A) All cases, (B) cases of vitrectomy combined with cataract surgery, (C) cases of 
vitrectomy. Data are presented as the mean+SE. *P<0.05 (VIT group vs IVTA+VIT group). D, day; M, month; PC, photon count; W, week.
Figure 3 Changes in the intensity of central retinal thickness (A), best-corrected visual acuity (B) and intraocular pressure (C) in the eyes of the 
patients who underwent vitrectomy (VIT group) or vitrectomy combined with intravitreal injection of triamcinolone acetonide (IVTA) (VIT+IVTA group). 
Data are presented as the mean+SE. D, day; M, month; W, week.
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difference of the ratio was insignificant between the groups (χ2 
test). Reoperation of vitrectomy was carried out in one case of 
the VIT group at 5 months after initial surgery, and in the other 
cases, VH was absorbed spontaneously. The onsets of retinal 
detachment and endophthalmitis were not observed in both 
groups through the observational periods.
dIsCussIon
Inflammation is a non-specific response to surgical invasion 
and laser photocoagulation. After cataract surgery and laser 
procedures, intraocular levels of proinflammatory cytokines 
are upregulated, which leads to worsening of DME.10–13 It has 
been reported that combination therapy of IVTA with cataract 
surgery or photocoagulation effectively reduced inflammation 
and related ocular complications.14–17 Similar to those findings, 
our results demonstrated that the flare intensity after surgery 
in the eyes combined with IVTA was significantly lower than 
that of vitrectomy only. These results suggest that IVTA can also 
effectively reduce the inflammation induced by surgical inva-
sion and photocoagulation. Our data also showed that the AFI 
in IVTA+VIT group was significantly lower compared with that 
in VIT group in both cases of vitrectomy combined with and 
without cataract surgery. Thus, regardless of having the combi-
nation of cataract surgery or not, the additional treatment of 
IVTA with vitrectomy may be effective option to inhibit the 
postoperative inflammation.
To reduce the risks of onset or progression of neovascular-
isation and rubeotic glaucoma, photocoagulation is routinely 
performed in the ischaemic area of the peripheral retina 
during vitrectomy. However, laser photocoagulation may be 
an important factor in the postoperative anterior inflamma-
tion.11 18 19 Actually, our data showed that there was a positive 
correlation between the number of laser shots and AFI in the VIT 
group. In contrast, this significant relationship was not observed 
Figure 4 Relationship between the anterior flare intensity at 1 week after surgery and the number of photocoagulations in the vitrectomy (VIT) 
group (A) and intravitreal injection of triamcinolone acetonide (IVTA) +VIT group (B). There was a significant correlation in the VIT group (A; P=0.024, 
R2=0.162) but not in the IVTA+VIT group (P=0.221). PC, photon count; .
Figure 5 The changes in central retinal thickness (CRT) (A) and visual acuity (B) in the VIT group and intravitreal injection of triamcinolone 
acetonide (IVTA)+VIT group in the patients with significant macular oedema. Data represent the mean±SE. *P<0.05 (VIT group vs IVTA+VIT group). 
#P<0.05 (compared with CRT at 3 days after vitrectomy). D, day; logMAR, logarithm of the minimum angle of resolution; M, month; W, week.
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in the IVTA+VIT group, which indicated that IVTA potentially 
could inhibit inflammation after surgery even if the number of 
laser spots was relatively greater.
It is recognised that thermal burns induce transient elevation 
of inflammatory cytokines in the vitreous or aqueous humour, 
which indicates induction of inflammation.12 20 We recently 
showed that IVTA combined with PRP in the eyes of pigmented 
rabbit suppressed both the expression of VEGF and of proin-
flammatory cytokines, whereas bevacizumab, an anti-VEGF 
drug, prevented VEGF only.18 These findings suggest that TA 
acts as a multipotency agent with anti-inflammatory and VEGF 
expression inhibitory properties. The inhibitory effect of AFI by 
the combination therapy of IVTA may be related to the reduc-
tion of cytokine levels after vitrectomy with photocoagulation. 
This may be supported by the report that the AFI was signifi-
cantly correlated with the levels of inflammatory cytokines in 
the vitreous fluid of the eyes with DME.21 In addition to the 
inflammation induced by cytokines, disruption of blood ocular 
barrier may also be largely involved in the pathology of the 
enhancement of AFI. Steroid treatment may have a potential to 
protect the disruption of blood ocular barrier in patients with 
PDR.
Several clinical trials have demonstrated that IVTA effectively 
reduced CRT in DME of both vitrectomised and non-vitrecto-
mised eyes.20 22 We were interested in determining whether the 
combination of IVTA with vitrectomy contributes to reduction 
of DME postoperatively. Based on all of our data, no signifi-
cant differences were found between the two groups. This 
finding may be because approximately 60% of the patients in 
each group had little macular swelling, and the normal ranges 
of CRT will not show further thinning or anatomical improve-
ment after surgery. Thus, we focused on the patients with DME 
who exhibited >350 µm in CRT at 3 days postoperatively. 
Limited to this patient series, CRT was significantly lower in 
the IVTA+VIT group than in the VIT group at 1 month after 
surgery. We speculate that additional IVTA could potentially 
accelerate improvement of DME, though the effect was limited 
in the early period after vitrectomy. Within the subgroup of 
macular oedema, the patients who underwent ERM or ILM 
peeling were equally distributed in IVTA+VIT group and VIT 
group. Although ERM or ILM peeling may have positive effect 
in reducing CRT, it is unlikely that these additional procedures 
resulted in the large differences in the postoperative changes of 
CRT between the groups.
The pharmacological effect of IVTA is time limited, and the 
intravitreal concentration of TA is detectable up to 2.75 months 
after a single 4 mg injection in non-vitrectomised human eyes.23 
TA may be washed out faster in vitrectomised eyes than in 
non-vitrectomised eyes.24 However, a clinical report by Wata-
nabe et al did not find a significant difference in the efficacy 
to reduce macular thickness after IVTA between vitrectomised 
and non-vitrectomised eyes, which indicated that IVTA may be 
a valid treatment option for DME even in vitrectomised eyes.20 
Even if TA is washed out relatively faster, it may be sufficient to 
inhibit the inflammation induced in the early stage after surgery.
Corticosteroids, either topically or systemically administered, 
have a risk of IOP elevation. However, our results showed that 
the addition of IVTA did not affect IOP postoperatively, and no 
eye showed uncontrollable IOP elevation. The reason remains 
unclear, however, it is possible that the increased clearance of 
TA by removal of the vitreous also reduces the risk of steroid-re-
lated complications, such as IOP elevation. Actually, Beer et al 
reported that the half-life of TA in the aqueous humour was 
18.6 days in the non-vitrectomised eyes, whereas it was only 3.2 
days in the vitrectomised eyes.25 Cataract formation is the other 
main ocular complication induced by IVTA. In our study, the 
IVTA+VIT group included no case of lens-sparing vitrectomy. 
However, if the cases of lens-sparing vitrectomy were encoun-
tered, we should pay attention for the risks of the progression 
of cataract which may be induced by IVTA postoperatively. In 
our patient series, onset of endophthalmitis, retinal detachment 
or other complications with IVTA were observed. Also, it is 
unlikely that IVTA affects the incidence of recurrent VH after 
surgery. However, further large-scale studies are necessary to 
evaluate the safety of combination therapy with IVTA.
We have a limitation that should be considered. We enrolled 
patients with PDR and VH, and thus, we could not determine 
the CRT before vitrectomy and how the CRT changed during 
the 3 days after surgery. To resolve this problem, participants 
should be selected more strictly by limiting selection to partici-
pants with DME without VH.
In conclusion, we studied the effects of IVTA on AFI and CRT 
after vitrectomy and cataract surgery for PDR. The combina-
tion of IVTA with vitrectomy may contribute to the reduction of 
CRT, however, the effect seems to be limited in the early stage 
after surgery. On the basis of our data, we recommend that IVTA 
should be administered at the end of vitrectomy and cataract 
surgery to achieve less inflammation for PDR with VH in the 
early stage after surgery.
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